MSN Laboratories Pvt. Ltd.
http://www.msnlabs.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MSN Laboratories Pvt. Ltd.
Jardiance, Trajenta Wins: Boehringer Takes Rough With Smooth In India
Boehringer Ingelheim tackles infringement activity pertaining to Trajenta and Jardiance in India, at least for now, but more action appears to be in the wings. The private German group remains confident that Jardiance will retain its preferred treatment choice status in the country for type 2 diabetes - but can the blockbuster therapy shake up the heart failure segment as well?
Novartis MS Franchise Boosted After Fending Off Last Gilenya Challenge
The Swiss firm expects no generic versions of Gilenya in the US market "for at least the next two years" after a court again ruled against HEC Pharma, the only remaining company challenging its patent.
B-Ingelheim India Chief On Strategy, Jardiance Challenge, Gender Balance In Pharma
Boehringer Ingelheim’s Country Managing Director for India Vani Manja outlines how she expects to shape the German group’s growth trajectory in the country, while also dealing with the unexpected pre-expiry challenge to the Jardiance patent. The executive also discusses her personal career journey, learnings from her prior role in the US and gives advice to women executives seeking to move up to the higher echelons of the corporate world.
High Stakes: Boehringer Faces Pre-Expiry India Jardiance Challenge
Indian firms debut empagliflozin copies ahead of expected patent expiry for diabetes blockbuster Jardiance in the country. Spotlight now on how swiftly Boehringer Ingelheim can fend off the entrants and whether the local challenge goes well beyond “inspiration” from the goings-on in the case of another SGLT2 inhibitor dapagliflozin.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs